Cargando…
Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
| Autores principales: | , , , , , , , , , |
|---|---|
| Formato: | Online Artículo Texto |
| Lenguaje: | English |
| Publicado: |
Elsevier
2023
|
| Materias: | |
| Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319311/ https://www.ncbi.nlm.nih.gov/pubmed/37409313 http://dx.doi.org/10.1016/j.jdin.2023.05.006 |
| _version_ | 1785068222150606848 |
|---|---|
| author | Bagit, Ahmed Maliyar, Khalad Georgakopoulos, Jorge R. Rankin, Brian Rimke, Alexander Mufti, Asfandyar Le, Heather Vender, Ronald Prajapati, Vimal H. Yeung, Jensen |
| author_facet | Bagit, Ahmed Maliyar, Khalad Georgakopoulos, Jorge R. Rankin, Brian Rimke, Alexander Mufti, Asfandyar Le, Heather Vender, Ronald Prajapati, Vimal H. Yeung, Jensen |
| author_sort | Bagit, Ahmed |
| collection | PubMed |
| description | |
| format | Online Article Text |
| id | pubmed-10319311 |
| institution | National Center for Biotechnology Information |
| language | English |
| publishDate | 2023 |
| publisher | Elsevier |
| record_format | MEDLINE/PubMed |
| spelling | pubmed-103193112023-07-05 Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class Bagit, Ahmed Maliyar, Khalad Georgakopoulos, Jorge R. Rankin, Brian Rimke, Alexander Mufti, Asfandyar Le, Heather Vender, Ronald Prajapati, Vimal H. Yeung, Jensen JAAD Int Research Letter Elsevier 2023-05-26 /pmc/articles/PMC10319311/ /pubmed/37409313 http://dx.doi.org/10.1016/j.jdin.2023.05.006 Text en © 2023 by the American Academy of Dermatology, Inc. Published by Elsevier Inc. https://creativecommons.org/licenses/by/4.0/This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/). |
| spellingShingle | Research Letter Bagit, Ahmed Maliyar, Khalad Georgakopoulos, Jorge R. Rankin, Brian Rimke, Alexander Mufti, Asfandyar Le, Heather Vender, Ronald Prajapati, Vimal H. Yeung, Jensen Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title | Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title_full | Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title_fullStr | Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title_full_unstemmed | Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title_short | Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| title_sort | real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: a multicenter retrospective study of switching within the interleukin-23 inhibitor class |
| topic | Research Letter |
| url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10319311/ https://www.ncbi.nlm.nih.gov/pubmed/37409313 http://dx.doi.org/10.1016/j.jdin.2023.05.006 |
| work_keys_str_mv | AT bagitahmed realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT maliyarkhalad realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT georgakopoulosjorger realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT rankinbrian realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT rimkealexander realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT muftiasfandyar realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT leheather realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT venderronald realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT prajapativimalh realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass AT yeungjensen realworldeffectivenessandsafetyofrisankizumabinpatientswithplaquepsoriasisinwhomguselkumabfailedrecentlyamulticenterretrospectivestudyofswitchingwithintheinterleukin23inhibitorclass |